Valaciclovir (INN) or Valacyclovir (USAN) is a prodrug and constructed
purine nucleoside alternation with inhibitory action adjoin canker canker virus
types 1 (HSV-1), 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus
(EBV), and cytomegalovirus (CMV). Valaciclovir is about absolutely adapted to
acyclovir and L-valine. The inhibitory action of valaciclovir is awful careful
due to its affection for the agitator thymidine kinase (TK) encoded by HSV and
VZV. This viral agitator converts acyclovir into acyclovir monophosphate, which
is again adapted into acyclovir diphosphate and triphosphate by cellular
enzymes. Acyclovir is selectively adapted to the alive triphosphate anatomy by
beef adulterated with canker viruses.
Valaciclovir is rapidly and about absolutely (~99%) adapted to the alive
compound, acyclovir, and L-valine by first-pass abdominal and hepatic
metabolism by enzymatic hydrolysis. Neither valaciclovir nor acyclovir is
metabolized by cytochrome P450 enzymes.
